Compugen Ltd. (NASDAQ:CGEN) Short Interest Down 18.1% in October

Compugen Ltd. (NASDAQ:CGEN) saw a significant decrease in short interest in the month of October. As of October 31st, there was short interest totalling 1,270,000 shares, a decrease of 18.1% from the October 15th total of 1,550,000 shares. Based on an average daily trading volume, of 225,400 shares, the days-to-cover ratio is currently 5.6 days.

Wall Street Analysts Forecast Growth

Separately, StockNews.com upgraded shares of Compugen from a “hold” rating to a “buy” rating in a research note on Thursday, August 15th.

Compugen Price Performance

NASDAQ:CGEN opened at $1.41 on Friday. The company has a market capitalization of $125.82 million, a P/E ratio of 70.50 and a beta of 2.64. The business has a fifty day simple moving average of $1.75 and a two-hundred day simple moving average of $1.87. Compugen has a 1 year low of $0.61 and a 1 year high of $3.03.

Compugen (NASDAQ:CGEN) last announced its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported $0.01 earnings per share for the quarter, missing the consensus estimate of $0.21 by ($0.20). The firm had revenue of $17.13 million during the quarter, compared to analysts’ expectations of $17.67 million. Compugen had a return on equity of 2.62% and a net margin of 2.67%. During the same period last year, the business posted ($0.11) EPS. As a group, analysts anticipate that Compugen will post 0.07 earnings per share for the current year.

Institutional Trading of Compugen

Several hedge funds and other institutional investors have recently modified their holdings of CGEN. ARK Investment Management LLC grew its stake in Compugen by 4.7% in the 2nd quarter. ARK Investment Management LLC now owns 1,088,271 shares of the biotechnology company’s stock valued at $1,850,000 after buying an additional 48,979 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. boosted its holdings in shares of Compugen by 82.7% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 274,335 shares of the biotechnology company’s stock worth $497,000 after acquiring an additional 124,190 shares during the period. Rothschild Investment LLC purchased a new position in shares of Compugen in the second quarter valued at $380,000. Atom Investors LP raised its stake in shares of Compugen by 27.5% during the 3rd quarter. Atom Investors LP now owns 151,816 shares of the biotechnology company’s stock valued at $275,000 after purchasing an additional 32,701 shares during the period. Finally, Squarepoint Ops LLC lifted its holdings in Compugen by 23.4% during the 2nd quarter. Squarepoint Ops LLC now owns 85,693 shares of the biotechnology company’s stock worth $144,000 after purchasing an additional 16,253 shares in the last quarter. Institutional investors own 12.22% of the company’s stock.

Compugen Company Profile

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company’s immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer.